Olmesartan Medoxomil

Management of Hypertension

Olmesartan medoxomil is primarily used to treat high blood pressure (hypertension). It belongs to a group of medications known as angiotensin II receptor blockers (ARBs). By lowering blood pressure, this medication helps reduce the risk of life-threatening cardiovascular events, such as:

• Stroke
• Heart attack
• Kidney problems

It is approved for use in adults and children who are at least 6 years of age.

Treatment Approaches

Healthcare providers may prescribe olmesartan medoxomil in different ways depending on the patient's needs:

• Single-drug therapy: It can be used as the only medication to manage blood pressure.
• Combination therapy: It is frequently used alongside other types of blood pressure medications, such as diuretics or calcium channel blockers, when one drug alone is not enough to reach target blood pressure levels.

It is important to note that olmesartan medoxomil manages high blood pressure but does not cure it. Patients often need to take it long-term, even if they feel well, to maintain healthy blood pressure levels and protect against heart failure or organ damage.

Mechanism of Action

Olmesartan medoxomil works by blocking the action of a natural substance in the body called angiotensin II. Angiotensin II is a hormone that causes blood vessels to tighten and narrow. When blood vessels are narrow, the heart must work harder to pump blood through them, which increases blood pressure.

By blocking the receptors for angiotensin II, this medication allows the blood vessels to:

• Relax and widen
• Allow blood to flow more easily
• Reduce the overall pressure within the cardiovascular system

Olmesartan medoxomil is considered a prodrug. This means that after you swallow the tablet, your body converts it into its active form, olmesartan, so it can begin working to manage your blood pressure.

Common Side Effects

Many people using this medication do not have serious side effects. Common symptoms may include:

• Dizziness or lightheadedness, especially when getting up from a sitting or lying position
• Headache
• Back pain
• Cold or flu-like symptoms, such as a sore throat, runny nose, or sinus congestion
• Diarrhea

Serious Side Effects

Contact your healthcare provider immediately if you experience any of the following serious side effects:

• Severe or chronic diarrhea: This may occur months or years after starting the drug and can lead to significant weight loss (sprue-like enteropathy).
• Kidney problems: Signs may include changes in the amount of urine or swelling in the hands, ankles, or feet.
• High potassium levels: Symptoms can include muscle weakness or a slow and irregular heartbeat.
• Fainting: Severe lightheadedness or loss of consciousness.

Seek emergency medical help if you notice signs of a serious allergic reaction, such as a rash, severe dizziness, swelling of the face, tongue, or throat, or difficulty breathing.

Fetal Toxicity

Olmesartan medoxomil can cause injury or death to an unborn baby if taken during pregnancy. Use of this medication should be discontinued as soon as pregnancy is detected. It is not recommended for use during the second and third trimesters of pregnancy because of the risk of fetal harm.

Sprue-like Enteropathy

A serious intestinal condition called sprue-like enteropathy has been reported in patients taking olmesartan. Symptoms include severe, chronic diarrhea and significant weight loss. This condition may develop months or even years after starting the medication. If these symptoms occur, healthcare providers may evaluate the patient for other causes and consider stopping the drug if no other cause is found.

Low Blood Pressure (Hypotension)

Patients with an activated renin-angiotensin system, such as those who are salt- or volume-depleted (for example, those treated with high doses of diuretics), may experience excessively low blood pressure after starting treatment. Monitoring is typically required when beginning therapy or increasing the dose.

Kidney Function and Electrolytes

Olmesartan may affect kidney function, particularly in individuals with pre-existing renal disease or severe heart failure. There is also a risk of hyperkalemia (high potassium levels in the blood), especially in patients with kidney impairment or diabetes. Periodic monitoring of serum creatinine and potassium levels may be necessary for those at risk.

Drug Interactions

The use of olmesartan in combination with aliskiren is contraindicated in patients with diabetes. Combining these medications increases the risk of kidney impairment, low blood pressure, and high potassium levels. Caution is also advised when using olmesartan with other drugs that affect the renin-angiotensin system or nonsteroidal anti-inflammatory drugs (NSAIDs).

Pregnancy Risks

Olmesartan carries a boxed warning because it can cause severe injury or death to a developing fetus. This risk is highest when the medication is taken during the second and third trimesters of pregnancy. If you become pregnant while taking this medication, you should contact your healthcare provider immediately to discuss alternative treatments. Olmesartan is typically discontinued as soon as pregnancy is confirmed.

Potential complications for the fetus or newborn include:

• Reduced kidney function or kidney failure
• Low levels of amniotic fluid (oligohydramnios)
• Underdeveloped lungs
• Deformities of the skull, face, or limbs
• Low blood pressure (hypotension) after birth

Breastfeeding Considerations

It is currently unknown whether olmesartan passes into human breast milk. Because many drugs are excreted in milk and there is a potential for serious side effects in nursing infants, healthcare providers generally recommend either stopping the medication or stopping breastfeeding. Patients should discuss the benefits of the medication versus the potential risks to the infant with their doctor to determine the most appropriate course of action.

Available Forms

Olmesartan medoxomil is supplied in the following form:

• Oral Tablet: This medication is a film-coated tablet intended to be taken by mouth.

The tablets are typically round or oval-shaped. The specific appearance of the medication, including color and markings, may vary depending on the manufacturer.

FDA Approval and Indications

Olmesartan medoxomil was approved by the U.S. Food and Drug Administration (FDA) to treat hypertension (high blood pressure) in adults and children aged 6 years and older. It may be used alone or in combination with other blood pressure medications to help lower blood pressure and reduce the risk of cardiovascular events like strokes and heart attacks.

Boxed Warning: Fetal Toxicity

The FDA requires a boxed warning for olmesartan medoxomil because drugs that act directly on the renin-angiotensin system can cause injury or death to a developing fetus. Use of the drug should be discontinued as soon as pregnancy is detected.

Major Safety Communications

• Sprue-like Enteropathy: The FDA issued a safety communication and approved label changes to include warnings about sprue-like enteropathy. This condition involves severe, chronic diarrhea with substantial weight loss and can develop months to years after starting the medication. If a patient develops these symptoms and no other cause is found, the drug should be discontinued.
• Dual Blockade of the Renin-Angiotensin System: The FDA has warned against using olmesartan in combination with aliskiren in patients with diabetes or kidney impairment. This combination increases the risk of hypotension (low blood pressure), hyperkalemia (high potassium), and changes in kidney function, including acute kidney failure.

Generic Availability

Olmesartan medoxomil is available as a generic drug, which is the bioequivalent of the brand-name medication Benicar. Generic versions are typically much less expensive than brand-name products because the manufacturers do not have to repeat the initial clinical trials or marketing expenses associated with a new drug.

Insurance Coverage

Most health insurance plans, including Medicare Part D and Medicaid, provide coverage for the generic version of olmesartan medoxomil. It is frequently listed on the lowest cost-sharing tiers of insurance formularies. Patients may find that their insurance requires the use of the generic version unless a medical necessity for the brand-name drug is established.

Cost Variables

The out-of-pocket cost for olmesartan medoxomil can vary based on several factors:

• Pharmacy Pricing: Different pharmacies may have different retail prices for the same generic medication.
• Prescription Size: Obtaining a 90-day supply through a mail-order pharmacy or local retailer can sometimes lower the cost per tablet compared to a 30-day supply.
• Savings Programs: For individuals without insurance, various pharmacy discount programs or coupons may help lower the cost of the generic medication at the point of sale.